OncoSec Announces First Patient Enrolled in Phase II Clinical Trial Evaluating Combination of ImmunoPulse™ IL-12 and Anti-PD-1 Treatment

OncoSec Medical Incorporated

today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco (UCSF) to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse™ IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic melanoma. The primary endpoint is the best Overall Response Rate (bORR) of the combination regimen in patients whose tumors are characterized by low numbers of tumor-infiltrating lymphocytes (TILs).   "There is increasing evidence that tumors need to be inflamed and have TILs in order for anti-PD-1 therapies to be most effective," said Mai H. Le, MD, Chief Medical Officer of OncoSec. "Both preclinical and clinical evidence suggest that ImmunoPulse™ IL-12 can promote tumor immunogenicity. We anticipate that ImmunoPulse™ IL-12 will increase the proportion of patients who will respond to immune checkpoint inhibitors like KEYTRUDA® and that the combination will have synergistic anti-tumor activity." "This is the first study in the field of immuno-oncology to evaluate the combination of DNA-based interleukin-12 with electroporation and an anti-PD-1/PD-L1 inhibitor," said Punit Dhillon, CEO and